Elan Corporation, plc (ADR) (ELN), VIVUS, Inc. (VVUS), MannKind Corporation (MNKD): Three Biotech Companies to Watch This Summer

Page 1 of 2

The news flow from biotech companies might slow down during the summer, but it won’t stop. In fact, a few biotechs are expecting news that could move their stock substantially. Here are three biotech companies to keep your eye on while you’re hanging out at the beach.

Up for sale
After Elan Corporation, plc (ADR) (NYSE:ELN) failed to convince its shareholders that its new business model was the right one, the biotech company formally put itself up for sale last Friday.

Elan Corporation, plc (ADR) (NYSE:ELN)

I figured it would take a couple of months for the bankers to start dropping hints as to who might be interested. Instead, it we got the first one in less than a week, as Reuters reported Wednesday that Forest Laboratories, Inc. (NYSE:FRX) was mulling a bid according to “people familiar with the situation.” I expect we’ll get a lot more unnamed sources paraphrased in articles as the summer progresses and as Elan Corporation, plc (ADR) (NYSE:ELN)’s bankers try to get the most bidders to the table.

Royalty Pharma previously offered $13 per share plus $2.50 in contingent value rights if Tysabri hits certain milestones. Since management wasn’t willing to accept that offer, we can assume an acquisition offer will have to be higher than that.

My guess is that any offer that Elan Corporation, plc (ADR) (NYSE:ELN) gets, will probably similarly contain a CVR, which allows the two sides to agree to disagree to the potential upside, while still getting the deal done. The only question now is whether Elan can find someone willing to pay a base price above the current market price.

A take-under — where CVR helps make up the price difference — is certainly an option and is the biggest risk to owning the stock beyond Elan Corporation, plc (ADR) (NYSE:ELN) not being able to find a bidder altogether.

Obesity catfight
VIVUS, Inc. (NASDAQ:VVUS)
will launch fights on two fronts this summer.

The biotech company’s obesity drug Qsymia now has direct competition from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai‘s recently launched Belviq. I continue to think there’s plenty of room for both drugs on the market; obesity is an epidemic after all. But in the short term, it’s going to be interesting to see if the launch of Belviq cuts into Qsymia sales.

VIVUS, Inc. (NASDAQ:VVUS) will also be waging a proxy war against the largest shareholder, First Manhattan, which is trying to unseat the board at the company’s annual meeting on July 15. First Manhattan claims that Qsymia’s slow launch is because the board doesn’t have the commercial expertise.

I’m not sure if VIVUS, Inc. (NASDAQ:VVUS)’ shareholders will buy it, and even if they do, it’s not clear that a change will make a material difference on the launch. Nevertheless, the fight will be a distraction for the next month, which certainly isn’t going to help with the biotech company’s launch.

Last clinical trials!
MannKind Corporation (NASDAQ:MNKD)
has been developing its inhaled insulin product Afrezza for years. The FDA rejected the drug-device combo in 2010, requesting additional information on the clinical utility of Afrezza.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!